These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 22610940

  • 1. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P, Wöhrer A, Hassler M, Hainfellner J, Preusser M, Marosi C.
    J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD.
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [Abstract] [Full Text] [Related]

  • 4. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R.
    Cancer; 2008 May 15; 112(10):2119-29. PubMed ID: 18338812
    [Abstract] [Full Text] [Related]

  • 5. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
    De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M, Agostini M, de Braud F.
    J Thorac Oncol; 2008 Aug 15; 3(8):938-41. PubMed ID: 18670317
    [Abstract] [Full Text] [Related]

  • 6. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H.
    J Orthop Sci; 2010 Sep 15; 15(5):654-60. PubMed ID: 20953927
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF, Perry CM.
    Drugs; 2003 Sep 15; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [Abstract] [Full Text] [Related]

  • 8. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 15; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 15; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
    Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN.
    Ann Oncol; 2008 Oct 15; 19(10):1713-9. PubMed ID: 18515258
    [Abstract] [Full Text] [Related]

  • 12. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL, Li J, Li J, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun 15; 41(6):386-90. PubMed ID: 22932406
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A, Landreville S, De La Fouchardière A, Mascarelli F, Rivoire M, Penel N, Mouriaux F.
    Clin Exp Metastasis; 2014 Jun 01; 31(5):553-64. PubMed ID: 24652072
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. KIT and PDGF as targets.
    Verweij J.
    Cancer Treat Res; 2004 Jun 01; 120():117-27. PubMed ID: 15217221
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A.
    J Clin Oncol; 2014 Feb 10; 32(5):402-8. PubMed ID: 24378417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.